GLP-1 Employer Coverage Tracker: What the 2026 Data Actually Shows

By Kaden Coziar, Founder & Managing Editor · The RX Index Research

Some employer plans cover GLP-1 medications for weight management, but there is no single coverage percentage that describes every employer. KFF’s 2025 survey found coverage in the largest health plan at 19% of firms with at least 200 workers that offered health benefits, rising to 43% among firms with at least 5,000 workers. Other surveys study different employer populations and report different results. The comparison below preserves those differences instead of blending them into one national rate.

For an individual employee, the useful question is more specific: does this plan cover this medication, in this formulation, for this diagnosis, on the relevant date? This tracker separates employer-plan decisions from carrier and pharmacy-benefit-manager policies, and distinguishes implemented changes, historical announcements, and future changes. A formulary listing does not guarantee approval, and an insurer’s name does not identify an employer’s complete benefit design.

Different populations and measures: these percentages must not be averaged.

GLP-1 employer coverage statistics: how many employers cover weight-loss drugs?

Employer size, sampling method, survey timing, and the definition of coverage all matter. A nationally sampled survey of benefit-offering firms is not interchangeable with a membership or benefits-consulting survey. Report each figure alongside its employer population and reference year; do not turn the spread between surveys into a national average or a patient’s probability of approval.

The table retains the separate question and sample for each published survey. Survey-wide respondent totals are not necessarily the number who answered a particular GLP-1 question.

Compiled by The RX Index Research from the linked releases and graphics. Definitions, populations, sample bases and reference periods differ. These are not a pooled estimate. Research cutoff: September 25, 2026.

These findings answer different questions. Use the KFF size bands when discussing differences within that survey, and identify other organizations’ samples when quoting their results. Where a public release omits the number answering a specific question, we report that limitation rather than deriving a count from a rounded percentage.

Survey-wave distinction: BGH’s annual report describes a 72% coverage observation in 2025 and 60% in 2026 within that annual-survey comparison. Its separate February–March 2026 pulse survey found 67% among 105 participating employer members overall. The 67% pulse is not the annual series’ 2025 observation, and the 105 total is not a published GLP-1 question denominator.

What this tracker adds: a selected set of documented employer decisions and carrier policies, separated from survey results. A historical notice establishes what was announced then; it does not alone prove the same benefit is in force today.

Why do employer GLP-1 coverage surveys give different answers?

The surveys differ in employer size, sampling method, field period, and the coverage question asked. Some measure coverage specifically for weight management; others distinguish diabetes-only coverage from coverage for both diabetes and weight loss. These distinctions are part of the finding, not a reason to choose whichever percentage makes the strongest headline.

Within one survey, size-band comparisons can be informative. Across organizations, retain the population and year beside every percentage. None of these employer-level statistics tells an individual whether a prescription will pass their plan’s authorization rules.

What this data shows — and what it doesn’t

These are survey self-reports of plan design, not claims-verified access. They tell you whether a plan covers weight-loss GLP-1s at all — not how many employees actually get approved after prior authorization, and not what happens at the pharmacy counter. The named-plan tracker further down is a documented sample of public decisions, not a census of every U.S. employer.

Two honest limits are worth stating up front. First, “covered” does a lot of work: a plan can technically cover a drug and still gate it behind a BMI floor, prior authorization, a required program, and a lifetime fill cap — which is why the restrictions section below matters as much as the coverage rate. Second, samples differ, so year-over-year trends within one survey are more reliable than comparisons across surveys. We do not blend them, and neither should anyone quoting this page.

How we built this tracker

We compile published survey findings and public coverage decisions, retaining each source’s population, indication, scope and relevant dates. Direct employer documents, carrier notices, PBM announcements and official survey releases are preferred. Attributed reporting is labeled as such rather than treated as a plan document. Petitions, forums and social posts do not establish coverage.

Source publication, source review, policy effective date and a material change to this article are different events. A historical notice does not prove a policy remains unchanged indefinitely. Unknown effective dates or indications are marked as not established by the cited source.

Our rules, so a reader can reproduce the work:

• Used as evidence: direct employer and plan-sponsor documents, state employee-benefit pages, carrier and PBM coverage notices, board and trustee materials, official survey releases, and government or agency publications.
• Used for language only, never as evidence for a factual claim: forums and social posts. They tell us how people phrase their confusion; they do not establish what a plan covers.
• Excluded: unsupported employer directories or unverified claims of unchanged current coverage.
• Evidence tiers: A = employer/plan-sponsor primary source; B = carrier/PBM primary source, limited by the stated product and group; C = attributed reporting without our inspection of the underlying employer plan document. Tiers describe evidence type, not a blanket reliability score.
• Update rule: a source review advances that record’s review date; policy details change only with supporting evidence. A review without a substantive page change does not reset the article’s modification date.

Documented employer-plan decisions and carrier policies

These are selected public decisions, not a directory of current coverage at every employer. The records distinguish employer plans, carrier options and PBM announcements. A diabetes or other-indication status is not inferred when its source addresses weight loss only.

Published dates and effective dates refer to the events described, not proof that every group’s policy is unchanged today. Where not stated, cardiovascular, sleep-apnea and MASH coverage is also unknown. Confirm the exact product, formulation and plan year with the administrator.

Sources and evidence scope are linked in each row. Source review: September 25, 2026 where accessible; some publisher documents could not be retrieved independently during this update. Historical notices and reporting are not blanket verification of current benefits. Tier C is attributed reporting, not a company plan document inspected by this tracker.

These records show different mechanisms: an exclusion in a plan, a limit on eligible fills, a rider selected by a group, and taxable reimbursement outside the pharmacy benefit are not interchangeable. North Carolina’s later negotiation agreement is not proof of reinstated coverage. Cigna’s own employee decision does not apply to other Cigna client plans. Review the linked documents for the exact group and year.

Tracker changelog

Material edits to the article are dated separately from the effective dates of the policies it describes. The research cutoff is September 25, 2026; a historical announcement does not confirm an unchanged current benefit.

• September 25, 2026 — Substantive review. Refreshed survey editions and source links; removed the invalid drug-specific coverage-loss aggregate and corrected IFEBP claims-year labeling; clarified employer/carrier scope, reimbursement, formulation and source limits; added GIC, Health New England and an upcoming CVS Caremark announcement. Historical announcements and future effective dates are distinguished from current-policy verification.
• August 25, 2026 — Denominator disclosure added. Business Group on Health publishes 72% likely to continue coverage in 2027 and 10% likely not to continue among employers currently covering GLP-1s for weight management, but does not publish the respondent count for that follow-up question. The reported BGH percentages were not changed; this update clarifies that their subgroup denominator cannot be recovered from the public release.
• July 1, 2026 — Initial publication. Original publication date; the earlier blanket statement that every row was fully verified on this date is not repeated as a current verification claim.

Why plan design matters more than the insurer’s name

Two employees carrying the same insurer logo can have different benefits. A fully insured employer selects among the insurer’s available benefits and options, subject to applicable rules; a self-funded sponsor can make its own covered-benefit decisions within the rules that apply to that plan. The administrator or PBM logo alone does not establish selected coverage.

For example, the BCBS Michigan carrier notice describes a specific fully insured commercial product; the University of Michigan’s self-funded plan publishes a separate lifetime limit. Neither tells you the terms of a different employer’s plan. Renewal and rider choices also matter.

The BCBS Massachusetts notice permits eligible groups to purchase a rider, while Reuters’ Cigna reporting concerns Cigna’s own employees only. Ask your plan for its applicable Summary Plan Description, formulary and written authorization criteria.

Why the tracker separates diabetes, weight loss, sleep apnea, and heart disease

Coverage decisions can be indication-specific, product-specific, formulation-specific, or a combination. Check the prescribed product and formulation, diagnosis and written plan criteria, not just the active ingredient or insurer brand.

Ozempic and Wegovy both contain semaglutide; Mounjaro and Zepbound both contain tirzepatide. Their approved indications differ. Wegovy injection has a cardiovascular-risk-reduction indication for specified adults; Zepbound has an obstructive-sleep-apnea indication for specified adults. FDA also granted accelerated approval for Wegovy injection for specified adults with noncirrhotic MASH and moderate-to-advanced fibrosis. That indication is not simply “weight loss.” An approval for one formulation is not necessarily an approval for another, and FDA approval does not establish employer-plan coverage.

For each plan, a source that says nothing about cardiovascular, sleep-apnea or MASH coverage leaves that indication not stated, not affirmatively covered. A formulary exclusion, authorization denial, lifetime cap, reimbursement program and announced future formulary change are distinct statuses.

What restrictions employers add when they keep coverage

A covered benefit can still require authorization, clinical eligibility, a particular prescriber or program, or compliance with a fill limit. KFF’s 2025 survey found that 34% of covering firms with at least 200 workers required specified dietitian, case-manager or therapist contacts, or a lifestyle program.

The named records show why a single yes/no coverage field is insufficient. A formulary exclusion, lifetime benefit cap and denied authorization request are different problems and should be recorded separately. An old IFEBP prior-authorization percentage was conditional on a utilization-management subgroup, not on all employers with coverage; we do not present it as a universal rate.

The University of Michigan’s published limit is measured in eligible one-month fills, not a promise of two uninterrupted calendar years. Confirm formulation-specific limit and appeal rules with the plan before relying on a formulary listing.

Why employers are cutting or narrowing coverage

Employers report financial pressure from GLP-1 benefits, but list prices, manufacturer cash prices and an employer’s net claims cost are different measures. They should not be compared as though the plan pays the advertised retail price.

IFEBP’s 2026 materials report weight-loss GLP-1 spending at 11.4% of total annual claims for 2025 among corporate respondents providing the claims information, versus 10.5% for 2024 in its claims comparison graphic. The separate multiemployer/public-employer result is 14.7% for 2025. The corporate claims question has n=72, not the corporate coverage-question n=307. These are reported results for those groups, not a national claims estimate or net-return analysis.

A premium simulation is not an observed premium increase, and a medical-cost change alone does not establish net savings after drug costs. The surveyed claims measures above should not be mistaken for manufacturer cash prices or current costs for a particular employer.

Is employer GLP-1 coverage growing or shrinking?

The evidence shows coverage pullbacks in some employer surveys and named plans, but not one uniform national trend for every drug and employer. Separate observed coverage changes from intentions, and employer decisions from carrier or PBM formulary changes.

Mercer’s June 2026 release reports a 2026 survey fielded April 15–May 8, with 604 respondents overall including 481 employers with 500+ employees. The latter group is not the GLP-1 question’s published denominator. Its 2026 removals, possible 2027 removals and eligibility changes answer different questions and cannot be added together.

Sources: linked BGH annual report, Mercer 2026 release and CVS Health’s announced PBM change. Research cutoff: September 25, 2026; the October change is not yet treated as implemented.

Historical survey note: The earlier BGH pulse survey also reported 72% of covering employers likely to continue in 2027 and 10% unlikely; its follow-up question n was unpublished. That intention measure is not the annual survey’s separate 72% coverage observation for 2025, and neither is an implemented 2027 benefit.

Are employers required to cover GLP-1s?

Coverage depends on the plan’s funding arrangement, applicable law, indication and selected benefits. FDA approval does not itself require every employer plan to cover a medication. Self-funded and fully insured arrangements are not legally identical; public-employer plans should not automatically be described as ERISA plans. This overview is educational, not a determination of legal entitlement.

The relevant plan documents and applicable legal requirements must be considered together. The example below is not a national inventory of state requirements.

Limited examples from the linked DOL and North Dakota sources, not a comprehensive state-mandate inventory or benefits determination.

Medicare and Medicaid are outside this employer-plan dataset. CMS’s Medicare GLP-1 Bridge is a separate temporary demonstration operating July 1, 2026 through December 31, 2027 for eligible beneficiaries. It does not establish employer coverage. See the Medicare GLP-1 Bridge tracker for program-specific details.

What changed in the tracker this year?

This timeline selects publicly reported changes; it does not measure how prevalent these policies are nationwide. Dates below are announcement, implementation or formulary-listing dates as indicated, not a blanket current-plan verification.

• April 1, 2024: NC State Health Plan weight-loss exclusion takes effect; diabetes coverage preserved in its historical statement.
• May 1, 2024: University of Michigan begins counting applicable fills toward a lifetime weight-loss GLP-1 limit.
• January 2025 / renewal: BCBS Michigan removes specified weight-loss products from its fully insured large-group commercial benefit.
• October 7, 2025: Ohio DAS launches a separate taxable medication-reimbursement program; this is not reinstated insured pharmacy coverage.
• January 2026 / renewal: Ohio State narrows GLP-1 use in its employee plan; BCBS Massachusetts changes the specified commercial benefit with a rider option for eligible groups; Health New England changes its specified commercial benefit.
• 2026 plan year: STAT reports HCA weight-loss benefit exclusion; exact effective day not established.
• April and August 2026: U-M formulary lists Wegovy tablets and Wegovy HD respectively, subject to plan restrictions; listing does not remove the lifetime limit.
• July 1, 2026: Cigna ends weight-loss coverage for its own employees; Massachusetts GIC ends weight-management-only coverage for non-Medicare members while retaining specified other indications under criteria.

Announced / upcoming at the research cutoff: CVS Caremark says Zepbound will return as a preferred commercial template-formulary option October 1, 2026 for clients choosing weight-management coverage; this does not establish an employer’s chosen benefit or authorization outcome.

Cash-pay programs have different dose, product, eligibility and duration terms. Compare them separately in the GLP-1 Price & Access Tracker; a promotional cash price does not establish employer net cost or coverage.

Limitations: what this tracker does and doesn’t show

This is a documented sample of public plan decisions and published survey data — not a complete census of U.S. employers, and not a substitute for your own plan documents. Public-sector, university, and very large employers are overrepresented here because they publish benefits pages and board materials; most private employers never disclose their pharmacy design.

The honest caveats, stated plainly because they make the data more useful:

• Not every employer is here. Absence from Table 2 means no qualifying public record was included, not proof of coverage or exclusion.
• Carrier rules don’t bind every group. A carrier’s standard exclusion may not apply to self-funded employers that use that carrier only as an administrator.
• One employer, multiple plans. Large employers often offer several plans with different pharmacy rules; a single row cannot capture all of them.
• Timing varies. Changes can take effect at plan renewal, not only on January 1, so effective dates differ by group.
• Surveys measure design, not access. A “covered” drug can still be denied at prior authorization or capped by a fill limit.
• Evidence differs. Tier C rows are attributed reports, not underlying plan documents verified by us; some source pages blocked independent retrieval during this review. A historical A or B notice also cannot establish an unchanged benefit today.
• This is educational research, not advice. The documents that control your coverage are your plan’s current Summary Plan Description, formulary, and any written benefit determination. For medical decisions, consult your clinician; for benefits questions, your plan administrator.

How to cite this page

Cite this compilation while preserving the separate definitions and sources underlying each table. It is not a new representative survey and does not claim ownership of the cited organizations’ research.

Frequently asked questions

See the linked survey and plan documents above for the evidence behind these answers.

Sources and primary documents

• GoodRx, insurance coverage tracker (July 2026)
• Business Group on Health, 2027 strategy survey (August 2026)
• Business Group on Health, 2026 GLP-1 pulse survey
• Mercer, 2025 national survey
• Mercer, 2026 GLP-1 and cost-sharing release
• KFF, 2025 Employer Health Benefits Survey
• IFEBP, 2026 GLP-1 pulse survey
• IFEBP, 2026 corporate survey graphic
• IFEBP, 2026 claims comparison graphic
• Brown & Brown, 2026 pharmacy market trends
• WTW, September 2025 company release (syndicated)
• SHRM, 2026 benefits survey GLP-1 discussion
• North Carolina State Health Plan, March 2024 statement
• North Carolina Treasurer, October 2025 CVS agreement
• Ohio State University Health Plan, weight management
• University of Michigan, lifetime drug limits
• University of Michigan, formulary updates
• Blue Cross Blue Shield of Massachusetts, 2025 provider notice
• Blue Cross Blue Shield of Michigan, 2024 carrier alert (PDF)
• Ohio DAS, September 2025 reimbursement announcement
• Reuters, Cigna own-employee plan reporting
• STAT, HCA notice reporting (subscription may be required)
• OhioHealth, associate prescription benefits
• Massachusetts GIC, June 2026 update
• Health New England, GLP-1 coverage
• CVS Health, May 2026 Caremark announcement
• FDA, Wegovy MASH indication
• U.S. Department of Labor, governmental plans and ERISA
• North Dakota Insurance Department, ACA benchmark
• CMS, Medicare GLP-1 Bridge

Research cutoff: September 25, 2026. Source dates and verification limits appear with the individual records. This is not a claim that every historical policy remains in effect.